TY - JOUR
T1 - Inhibitory effect of antihypertensive drugs on calcineurin in cardiomyocytes
AU - Zhang, Gus Q.
AU - Zhu, Zhiming
AU - Zhang, Weiguo
PY - 2009/2/16
Y1 - 2009/2/16
N2 - In recent years, a handful of research investigations have shown that some antihypertensive drugs, i.e., angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), and calcium channel blocker (CCB), can inhibit myocardial expression and/or activity of calcineurin. Calcineurin is a Ca2+-calmodulin-dependent serine/threonine phosphatase and is a target for some immunosuppressive drugs. It is well known that traditional immunosuppressants, such as cyclosporine A (CsA) and tacrolimus (FK506), are anticalcineurin, and their prohypertensive effects are such that antihypertensive therapy is often required in organ transplant recipients who receive these drugs. Therefore, the idea that ACEI, ARB, and CCBs are both antihypertensive and anticalcineurin seems paradoxical. This invited review tries to summarize these new findings and analyze the scientific and clinical significance of these claims. The review also emphasizes some of the shortcomings in these studies and some questions that need to be addressed in future investigations.
AB - In recent years, a handful of research investigations have shown that some antihypertensive drugs, i.e., angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), and calcium channel blocker (CCB), can inhibit myocardial expression and/or activity of calcineurin. Calcineurin is a Ca2+-calmodulin-dependent serine/threonine phosphatase and is a target for some immunosuppressive drugs. It is well known that traditional immunosuppressants, such as cyclosporine A (CsA) and tacrolimus (FK506), are anticalcineurin, and their prohypertensive effects are such that antihypertensive therapy is often required in organ transplant recipients who receive these drugs. Therefore, the idea that ACEI, ARB, and CCBs are both antihypertensive and anticalcineurin seems paradoxical. This invited review tries to summarize these new findings and analyze the scientific and clinical significance of these claims. The review also emphasizes some of the shortcomings in these studies and some questions that need to be addressed in future investigations.
UR - http://www.scopus.com/inward/record.url?scp=58549110245&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58549110245&partnerID=8YFLogxK
U2 - 10.1038/ajh.2008.305
DO - 10.1038/ajh.2008.305
M3 - Review article
C2 - 18927543
AN - SCOPUS:58549110245
SN - 0895-7061
VL - 22
SP - 132
EP - 136
JO - American Journal of Hypertension
JF - American Journal of Hypertension
IS - 2
ER -